Literature DB >> 6692326

Staging and treatment of clinically occult breast cancer.

G F Schwartz, S A Feig, A L Rosenberg, A S Patchefsky, A B Schwartz.   

Abstract

Five hundred fifty-seven biopsies were performed for clinically occult mammary lesions, detected by mammography as clustered calcifications or nonpalpable masses within the breast. One hundred seventy-five cancers were demonstrated within this group, including 106 invasive carcinomas, 10 microinvasive carcinomas, 45 in situ ductal carcinomas, and 14 lobular carcinomas in situ (lobular neoplasia). No patient with in situ or microinvasive carcinoma had evidence of axillary node metastases in 33 specimens studied. However, a disturbingly high proportion of those patients with invasive carcinomas, approximately 35%, had histologically confirmed axillary node metastases, despite the small size of the primary tumors. These observations suggest that the use of the term "minimal" cancer is misleading when applied to invasive carcinoma. Staging systems for breast cancer have been imprecise when referring to nonpalpable lesions. Cancers detected as clustered calcifications only or as areas of parenchymal distortion without an accompanying mass are properly considered as T-0 cancers, with a suggested T-0(m) to indicate that the lesion was detected by mammography. However, when the mammogram indicates the presence of a mass that proves to be malignant, although the clinical examination may have been negative, the cancer should be staged according to the size of the mass on the mammogram, with the notation that it was detected by mammography, e.g., T-1(m), T-2(m), etc. The incidence of axillary node metastases even in these so-called occult cancers is significant, so that recommendations for treatment for any invasive cancer, regardless of its size, must take these observations into account. Similarly, the incidence of multifocal sites of cancer within the breast, even in the noninvasive cancers encountered, must be remembered when treatment is suggested.

Entities:  

Mesh:

Year:  1984        PMID: 6692326     DOI: 10.1002/1097-0142(19840315)53:6<1379::aid-cncr2820530627>3.0.co;2-r

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Treatment and survival of female patients with nonpalpable breast carcinoma.

Authors:  J G Tinnemans; T Wobbes; R Holland; J H Hendriks; R F Van der Sluis; H H De Boer
Journal:  Ann Surg       Date:  1989-02       Impact factor: 12.969

2.  Needle localization and surgical management of occult breast lesions.

Authors:  G Barnes; W E Matory
Journal:  J Natl Med Assoc       Date:  1989-06       Impact factor: 1.798

Review 3.  Management of in situ and minimally invasive breast carcinoma.

Authors:  E R Frykberg; K I Bland
Journal:  World J Surg       Date:  1994 Jan-Feb       Impact factor: 3.352

4.  Clinically occult breast carcinoma: diagnostic approaches and role of axillary node dissection.

Authors:  S Meterissian; B D Fornage; S E Singletary
Journal:  Ann Surg Oncol       Date:  1995-07       Impact factor: 5.344

Review 5.  [Is axillary dissection in clinically lymph node-negative breast carcinoma further indicated?].

Authors:  F K Böhler; H Eiter; W Rhomberg
Journal:  Strahlenther Onkol       Date:  1998-12       Impact factor: 3.621

Review 6.  Non-invasive breast carcinoma.

Authors:  M C Posner; N Wolmark
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

7.  Management of nonpalpable breast abnormalities.

Authors:  R E Symmonds; J W Roberts
Journal:  Ann Surg       Date:  1987-05       Impact factor: 12.969

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.